Pfizer (PFE) Debt to Equity (2009 - 2026)

Pfizer has disclosed Debt to Equity across 18 years of filings, most recently posting $0.72 for Q1 2026.

• In Q1 2026, Debt to Equity rose 4.39% year-over-year to $0.72; the TTM figure through Mar 2026 stood at $0.72 (up 4.39% YoY), while the FY2025 annual figure was $0.75, up 3.7% from the prior year.
• Debt to Equity eased to $0.72 in Q1 2026, from $0.75 in the prior quarter.
• Over the last five years, Debt to Equity for PFE reached as high as $0.81 in Q4 2023 and fell as low as $0.35 in Q2 2023.
• The 5-year median for Debt to Equity is $0.69 (2025), against an average of $0.63.
• Annual changes were most pronounced in 2022 — Debt to Equity slumped 64.38% — and 2023, when it soared 115.54%.
• A 5-year view of Debt to Equity shows it stood at $0.37 in 2022, then soared by 115.54% to $0.81 in 2023, then dropped by 10.25% to $0.72 in 2024, then advanced by 3.7% to $0.75 in 2025, then fell by 4.53% to $0.72 in 2026.
• According to Business Quant data, Debt to Equity over the past three periods registered $0.72, $0.75, and $0.66 for Q1 2026, Q4 2025, and Q3 2025 respectively.